These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 26021488)

  • 1. Impact of high dose n-3 polyunsaturated fatty acid treatment on measures of microvascular function and vibration perception in non-alcoholic fatty liver disease: results from the randomised WELCOME trial.
    McCormick KG; Scorletti E; Bhatia L; Calder PC; Griffin MJ; Clough GF; Byrne CD
    Diabetologia; 2015 Aug; 58(8):1916-25. PubMed ID: 26021488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial.
    Clough GF; McCormick KG; Scorletti E; Bhatia L; Calder PC; Griffin MJ; Byrne CD
    Diabetologia; 2016 Jul; 59(7):1422-1429. PubMed ID: 27106721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and rationale of the WELCOME trial: A randomised, placebo controlled study to test the efficacy of purified long chainomega-3 fatty acid treatment in non-alcoholic fatty liver disease [corrected].
    Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Calder PC; Byrne CD;
    Contemp Clin Trials; 2014 Mar; 37(2):301-11. PubMed ID: 24556343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of purified eicosapentaenoic and docosahexaenoic acids in nonalcoholic fatty liver disease: results from the Welcome* study.
    Scorletti E; Bhatia L; McCormick KG; Clough GF; Nash K; Hodson L; Moyses HE; Calder PC; Byrne CD;
    Hepatology; 2014 Oct; 60(4):1211-21. PubMed ID: 25043514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
    Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
    J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in non-alcoholic fatty liver disease severity is associated with a reduction in carotid intima-media thickness progression.
    Bhatia L; Scorletti E; Curzen N; Clough GF; Calder PC; Byrne CD
    Atherosclerosis; 2016 Mar; 246():13-20. PubMed ID: 26748347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of long-term vitamin D and n-3 fatty acid supplementation on inflammatory and cardiac biomarkers in patients with type 2 diabetes: secondary analyses from a randomised controlled trial.
    Limonte CP; Zelnick LR; Ruzinski J; Hoofnagle AN; Thadhani R; Melamed ML; Lee IM; Buring JE; Sesso HD; Manson JE; de Boer IH
    Diabetologia; 2021 Feb; 64(2):437-447. PubMed ID: 33098434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial.
    Hoogeveen EK; Geleijnse JM; Kromhout D; Giltay EJ
    Eur J Prev Cardiol; 2014 Nov; 21(11):1429-36. PubMed ID: 23774275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An association of large-fibre peripheral nerve dysfunction with non-invasive measures of liver fibrosis secondary to non-alcoholic fatty liver disease in diabetes.
    Williams KH; Burns K; Constantino M; Shackel NA; Prakoso E; Wong J; Wu T; George J; McCaughan GW; Twigg SM
    J Diabetes Complications; 2015; 29(8):1240-7. PubMed ID: 26297218
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial.
    Andrieu S; Guyonnet S; Coley N; Cantet C; Bonnefoy M; Bordes S; Bories L; Cufi MN; Dantoine T; Dartigues JF; Desclaux F; Gabelle A; Gasnier Y; Pesce A; Sudres K; Touchon J; Robert P; Rouaud O; Legrand P; Payoux P; Caubere JP; Weiner M; Carrié I; Ousset PJ; Vellas B;
    Lancet Neurol; 2017 May; 16(5):377-389. PubMed ID: 28359749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline blood levels of omega-3 and depression remission: a secondary analysis of data from a placebo-controlled trial of omega-3 supplements.
    Carney RM; Steinmeyer BC; Freedland KE; Rubin EH; Rich MW; Harris WS
    J Clin Psychiatry; 2016 Feb; 77(2):e138-43. PubMed ID: 26930527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Marine omega-3 fatty acid supplementation in non-alcoholic fatty liver disease: Plasma proteomics in the randomized WELCOME* trial.
    Manousopoulou A; Scorletti E; Smith DE; Teng J; Fotopoulos M; Roumeliotis TI; Clough GF; Calder PC; Byrne CD; Garbis SD
    Clin Nutr; 2019 Aug; 38(4):1952-1955. PubMed ID: 30172659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Docosahexaenoic acid enrichment in NAFLD is associated with improvements in hepatic metabolism and hepatic insulin sensitivity: a pilot study.
    Hodson L; Bhatia L; Scorletti E; Smith DE; Jackson NC; Shojaee-Moradie F; Umpleby M; Calder PC; Byrne CD
    Eur J Clin Nutr; 2017 Aug; 71(8):973-979. PubMed ID: 28294174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study.
    Eriksson JW; Lundkvist P; Jansson PA; Johansson L; Kvarnström M; Moris L; Miliotis T; Forsberg GB; Risérus U; Lind L; Oscarsson J
    Diabetologia; 2018 Sep; 61(9):1923-1934. PubMed ID: 29971527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating CD36+ microparticles are not altered by docosahexaenoic or eicosapentaenoic acid supplementation.
    Phang M; Thorne RF; Alkhatatbeh MJ; Garg ML; Lincz LF
    Nutr Metab Cardiovasc Dis; 2016 Mar; 26(3):254-60. PubMed ID: 26803595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of a High Concentrate Omega-3 for Correcting the Omega-3 Fatty Acid Nutritional Deficiency in Non-Alcoholic Fatty Liver Disease (CONDIN).
    Tobin D; Brevik-Andersen M; Qin Y; Innes JK; Calder PC
    Nutrients; 2018 Aug; 10(8):. PubMed ID: 30127297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: Results from two placebo-controlled interventions.
    Mas E; Woodman RJ; Burke V; Puddey IB; Beilin LJ; Durand T; Mori TA
    Free Radic Res; 2010 Sep; 44(9):983-90. PubMed ID: 20540666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No effect of n-3 fatty acids supplementation on NT-proBNP after myocardial infarction: the Alpha Omega Trial.
    Hoogeveen EK; Geleijnse JM; Kromhout D; van't Sant P; Gemen EF; Kusters R; Giltay EJ
    Eur J Prev Cardiol; 2015 May; 22(5):648-55. PubMed ID: 24879357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fatty acid and non-alcoholic fatty liver disease: Meta-analyses of case-control and randomized controlled trials.
    Guo XF; Yang B; Tang J; Li D
    Clin Nutr; 2018 Feb; 37(1):113-122. PubMed ID: 28161092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Nonalcoholic Fatty Liver Disease with Long-Chain n-3 Polyunsaturated Fatty Acids in Humans.
    Kelley NS
    Metab Syndr Relat Disord; 2016 Nov; 14(9):417-430. PubMed ID: 27710160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.